Please login to the form below

Not currently logged in

Akcea Therapeutics

This page shows the latest Akcea Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights emerging assets and late-stage pipeline at R&D day

Novartis highlights emerging assets and late-stage pipeline at R&D day

TQJ230, an antisense oligonucleotide it licensed from Akcea Therapeutics in February, which reduces Lp(a), a currently untreatable risk factor for cardiovascular disease – an outcomes trial of over 7, 500 patients

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...